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ow
nloadeAntigen-specific immune responses to protein drugs can hinder efficacy and compromise safety because of drug
neutralization and secondary clinical complications. We report a tolerance induction strategy to prevent antigen-
specific humoral immune responses to therapeutic proteins. Our modular, biomolecular approach involves engi-
neering tolerizing variants of proteins such that they bind erythrocytes in vivo upon injection, on the basis of the
premise that aged erythrocytes and the payloads they carry are cleared tolerogenically, driving the deletion of
antigen-specific T cells. We demonstrate that binding the clinical therapeutic enzyme Escherichia coli L-asparaginase
to erythrocytes in situ antigen-specifically abrogates development of antibody titers by >1000-fold and extends the
pharmacodynamic effect of the drug 10-fold in mice. Additionally, a single pretreatment dose of erythrocyte-binding
asparaginase tolerized mice to multiple subsequent doses of the wild-type enzyme. This strategy for reducing
antigen-specific humoral responses may enable more effective and safer treatment with therapeutic proteins and
drug candidates that are hampered by immunogenicity.d
 o
n
 June 21, 2016
http://advances.sciencem
ag.org/
 from
 INTRODUCTION
A growing focus on immunogenicity of protein drugs has paralleled
the expansion of their use in the advanced treatment of human disease.
Repeated administration of protein drugs can lead to the development
of undesired anti-drug antibodies and resultant drug neutralization,
infusion reactions, and serious adverse events (1, 2). It follows that a
variety of approaches that aim to induce immune tolerance to protein
therapies by co-administration with clinically approved immunomod-
ulating drugs have been proposed. For example, the small-molecule
anti-folate drug methotrexate, commonly used in the treatment of can-
cer and autoimmune disorders, has recently been shown to dampen
immunogenicity by expansion of interleukin-10–secreting regulatory
B cells during specific dosing regimens (3) and to have further promise
when paired with the proteasome inhibitor bortezomib to deplete
plasma cells during ongoing immune responses (4).
Other approaches rely on engineering less immunogenic variants
of protein therapeutics to attain improved immunogenicity profiles.
For example, strategies to shield therapeutic proteins from the immune
system have been steadily on the rise, and more than 10 products grafted
with polyethylene glycol (PEG) molecules are currently approved for
clinical use (5). Although reporting of anti-PEG immunity to these clin-
ical products is sparse in the literature, recent studies have highlighted
potential immunogenicity risks relating to PEGylation strategies, war-
ranting further investigation. For example, anti-PEG antibodies have
been clinically reported in 25% of normal healthy blood donors and in
46% of patients treated with PEGylated asparaginase (Oncaspar, Sigma-
Tau) (5, 6). Moreover, anti-PEG antibodies have been found to corre-
late with clinically significant increases in clearance of the therapeutic
(6, 7). Other engineering techniques seek to reduce unwanted immune
recognition by alteration of the core protein itself, either by removing
potential T and B cell epitopes (8–11) or by engineering human analogs to
reduce the degree of foreignness perceived by the patient’s immune system(12). Such epitope-based approaches have yielded promising preclinical
results and hold impressive potential for clinical development, yet are
complicated by the requirement for knowledge of the precise immuno-
dominant epitopes within the molecule, alteration of which may ablate
the biological function of the therapeutic and which may depend on the
specific human leukocyte antigen (HLA) alleles expressed by the subject.
Thus, there remains a pressing clinical need for a more general method
to reduce or prevent humoral immune responses to therapeutic proteins.
Here, we report a modular strategy to engineer induction of antigen-
specific tolerance to therapeutic proteins through targeted erythrocyte
binding. Antigens derived from apoptotic cells drive antigen-specific tol-
erance via deletion or anergy of reactive T cells (13, 14). Reasoning that
a large number of erythrocytes become apoptotic (eryptotic) and are
cleared each day, we engineered a strategy to bind model antigens to
erythrocytes in situ and consequently induce antigen-specific tolerance
in CD4 and CD8 T cells (15). We previously demonstrated antigen-
specific T cell exhaustion and deletion in the context of cellular im-
munity and prevention of autoimmunity; here, we focus instead on
humoral immunity, reasoning that the lack of CD4 T cell help to stim-
ulate B cell immunity may provide an approach to T cell–dependent
humoral immune tolerance. Using the clinical therapeutic enzyme
Escherichia coli L-asparaginase-II (ASNase) as our target antigen of interest,
we demonstrate that prophylactic administration of an erythrocyte-
binding bioconjugate of ASNase induces antigen-specific tolerance, as
evidenced by lack of marked formation of a humoral response during
long-term follow-on treatment with the wild-type form of ASNase. These
data effectively support a general tolerance induction approach to foreign
protein drugs, such as E. coli ASNase, including those that bear essentially
no sequence homology to a centrally tolerized endogenous protein.
RESULTS
Engineered variants of ASNase bind specifically to
erythrocytes and retain biological activity
The goal of our experimental design was to induce humoral immune
tolerance to a foreign therapeutic protein that suffers from clinically
relevant immunogenicity. ASNase is an enzyme used in the treatment
of acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphomas,1 of 10
R E S EARCH ART I C L Ewhere depletion of L-asparagine levels in patients is sought as a means
to eradicate cancerous cells that cannot themselves synthesize the amino
acid. Due to its highly foreign origin to human patients (and to mice,
as shown in our animal model), substantial ASNase-specific antibody
response rates (61 to 93%) are reported during clinical treatment, of
which 45 to 96% are estimated as neutralizing (16–18), making the drug
a prime candidate for tolerance induction strategies and development
of nonimmunogenic variants.
To achieve specific and high-affinity binding of ASNase to erythro-
cytes in situ after intravenous injection, we chemically conjugated several
copies of a glycophorin A–binding peptide (19) (ERY1) to clinical-Lorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015grade ASNase (Asparaginase 5000, Medac GmbH) (Fig. 1A). A detailed
description of the manufacturing process can be found in Materials and
Methods. The apparent affinity of the resulting erythrocyte-binding
asparaginase conjugate (ERY1-ASNase) was found to be in the nano-
molar range when assessed by flow cytometric measurement of cell-
associated ASNase after incubation of erythrocytes with titrated conjugate.
Binding of ERY1-ASNase to erythrocytes can be modulated by tuning
the ratio of the number of copies of ERY1 peptide to ASNase mono-
mer within our conjugation scheme (Fig. 1B).
For further study, we selected a conjugate with an apparent bind-
ing affinity of 5 nM (3 copies per monomer unit), corresponding to o
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Fig. 1. ASNase conjugation to the ERY1 peptide imparts long-term erythrocyte binding in vivo and enhanced pharmacodynamics of plasma
asparagine depletion. (A) Erythrocyte-binding ASNase is produced by chemically conjugating copies of the glycophorin A–binding peptide (ERY1) to
ASNase. (B) Characterization of apparent affinity values of ERY1-ASNase conjugates functionalized with varying molar equivalents of ERY1 peptide per ASNase
monomer, determined by flow cytometry (one-site binding, R2 ≥ 0.98 for all curve fits). (C) Specific enzymatic activity characterization of ERY1-ASNase and
wild-type (WT) ASNase, determined by a fluorogenic assay (n ≥ 4). (D) In vivo ERY1-ASNase binding specificity to erythrocytes (CD45−) but not to other blood
cell populations. (E) ERY1-ASNase binding (right panel) and WT ASNase nonbinding (left panel) to healthy (annexin V−) and apoptotic (annexin V+) erythro-
cytes (CD45−) 24 hours after a 15-mg intravenous injection, determined by flow cytometry. (F) Cell surface binding kinetics and half-life of ERY1-ASNase
bound to circulating erythrocytes after a single 15-mg intravenous injection, determined by flow cytometry (n = 3, one-phase decay, R2 = 0.97).
(G) Plasma asparagine (Asn) concentration of mice injected with a single 15-mg dose of either WT ASNase or ERY1-ASNase, determined by quantitative
liquid chromatography–mass spectrometry (LC-MS) [data presented as means ± SEM (n = 5); repeated once; dotted lines represent homeostatic plasma
asparagine concentrations (36)].2 of 10
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 the affinities used in our previous studies of cellular immune tolerance
(15). We used a fluorogenic ASNase activity assay to ensure that our
chemical modifications to attain erythrocyte binding did not reduce
the specific activity of the conjugated enzyme (Fig. 1C). Binding was
confirmed to be specific to erythrocytes (CD45−) and not to any leuko-
cyte populations (B cells, T cells, granulocytes, monocytes) in blood
(Fig. 1D), consistent with glycophorin A being present uniquely on
erythrocytes. Additionally, the binding of ERY1-ASNase to the eryth-
rocyte cell surface did not induce eryptosis, nor did residual eryptosis of
cells correlate with any binding bias, as suggested by strong ERY1-
ASNase binding to both annexin V–binding and non–annexin V–binding
populations (Fig. 1E).
Erythrocyte binding enhances the pharmacokinetic and
pharmacodynamic profiles of ASNase
We next examined the cell surface pharmacokinetic profile of ERY1-
ASNase to determine the duration of erythrocyte association in vivo.
The dosing of mice for all subsequent studies was determined by lin-
early scaling the human dose described in the clinical package insert.
Upon injection of a single 15-mg intravenous dose, ERY1-ASNase was
detectable on erythrocyte surfaces for about 2 weeks, with a cell sur-
face half-life of 50 hours (Fig. 1F), exceeding the previously reported in
vivo serum half-lives of ASNase and PEGylated ASNase in the mouse
(3 and 33 hours, respectively) (20).
We then explored the functional implications of the increased
pharmacokinetics of the erythrocyte-binding conjugate by measuring
the pharmacodynamic effect on plasma asparagine levels after a single
15-mg intravenous dose of ERY1-ASNase or wild-type ASNase. Treat-
ment with wild-type ASNase sustained plasma asparagine depletion in
mice to nondetectable levels for 2 days before rapid recovery within
8 days of injection. In contrast, administration of a single dose of ERY1-
ASNase yielded nondetectable levels of plasma asparagine for 25 days
(>10-fold longer than wild-type ASNase), subphysiological asparagine
levels for >35 days, and fully recovered physiological values at 45 days
after administration, confirming that ERY1-ASNase remains enzymat-
ically active as a tetramer when bound to circulating erythrocytes (Fig.
1G). These increases in pharmacokinetics and pharmacodynamics are
not unexpected, given the 40- to 60-day life span of a mouse erythrocyte
and the potential for ERY1-ASNase to disassociate and reassociate
with a neighboring erythrocyte, owing to their extremely high concen-
tration in the blood. Because sustained asparagine depletion is paramount
to treatment efficacy in ALL patients, the extension of the pharmaco-
dynamic effect is particularly relevant (21, 22).
To determine whether such stark improvements in asparagine de-
pletion dynamics altered immune cell populations, which could
confound our immunological interpretations, we performed extensive
phenotypic characterization of cell populations in the blood, bone
marrow, and spleen of mice injected with two weekly doses of ERY1-
ASNase or wild-type ASNase. In the blood, ERY1-ASNase treatment
induced no substantial alterations in hematological parameters as com-
pared to age-matched naïve mice, except for a slight (2.2%) increase in
mean corpuscular volume (Fig. 2A; flow cytometry gating in fig. S1
and full data in tables S1 and S2) and a slight decrease in B cells
(9.2%). Similar to our previous findings with erythrocyte-binding
ovalbumin (OVA) (15), the lack of hematological changes supports
the conclusion that ERY1-mediated association with the erythrocyte
surface does not alter erythrocyte function or phenotype. Wild-type
ASNase administration strongly trended toward increasing most leu-Lorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015kocyte population counts and erythrocyte parameters as compared to
naïve mice; however, these changes did not attain statistical signifi-
cance. For some parameters where ERY1-ASNase and wild-type ASNase
treatment yielded opposing changes from the naïve animals, such as in
hematocrit, white blood cell count, lymphocyte count, monocyte count,
and eosinophil count, the differences attained significance from each
other despite neither condition being significantly different from the
naïve values. Furthermore, it should be noted that because of these
opposing trends, the resulting ERY1-ASNase/wild-type ASNase ratio
represents an exaggerated yet conservative comparison to the overall
effect on tolerance induction. Although several population counts were
reduced when comparing ERY1-ASNase–treated mice to wild-type
ASNase–treated mice, the overall blood population distribution (de-
noted by percentages) was not altered, suggesting that the enhanced
pharmacokinetics of ERY1-ASNase may have resulted in the slight deple-
tion of several populations without skewing the repertoire in any dis-
cernible way. Furthermore, in ERY1-ASNase–treated mice, the decrease
in total B cells is slight, and the absence of alteration in subpopulations
suggests a lack of direct effect on tolerance induction. In the spleen,
both ERY1-ASNase and wild-type ASNase reduced the overall popu-
lations of B cells (by 14.3 and 6.0%, respectively) and follicular B cells
(by 15.8 and 6.6%, respectively) when compared to naïve mice, yet no
differences in any B cell populations (total, B1-B, marginal zone, fol-
licular) were detected when ERY1-ASNase and wild-type ASNase treat-
ments were compared (Fig. 2B; flow cytometry gating in figs. S2 to S4
and full data in tables S2 to S4). Although not statistically significant,
it is unknown whether the further reduction in total splenic B cells in
ERY1-ASNase–treated mice compared to wild-type ASNase–treated
mice is related to the greatly enhanced pharmacodynamic effect of
ASNase. In general, ASNase administration in either wild-type or
erythrocyte-binding form trended toward slightly increased levels of myeloid
and dendritic cell populations; however, a significant increase in cells was
only seen for the immature myeloid cell population (MHC-IIlow CD11b+)
after ERY1-ASNase treatment. In the bone marrow, increased popula-
tions of T cells (CD4) and T regulatory (Treg) cells (CD4 and CD8) were
detected in ERY1-ASNase–treated mice as compared to naïve mice; how-
ever, when compared to wild-type ASNase–treated mice, only CD4
T cell numbers were increased in ERY1-ASNase–treated mice (Fig. 2C;
flow cytometry gating in figs. S2, S4, and S5 and full data in tables S2, S4,
and S5). ERY1-ASNase also slightly reduced the numbers of mature my-
eloid cells (MHC-II+ CD11b+) in the bone marrow when compared to
wild-type ASNase–treated or naïve mice. No differences in any of the
measured B cell populations (total, early mature, mature, pro- and
pre-B, transitional) were detected in the bone marrow. Together, our
multiorgan phenotypic analyses indicate that administration of ERY1-
ASNase does not nonspecifically deplete the main immune cell popu-
lations that drive humoral immunogenicity.
Erythrocyte-binding ASNase induces sustained
antigen-specific tolerance to multiple follow-on
challenges with antigen
We next tested the tolerogenic capacity of ERY1-ASNase in various treat-
ment schemes in mice, measuring antigen-specific humoral responses
over time. Specifically, each treatment scheme consisted of eight weekly
15-mg intravenous doses of wild-type ASNase or ERY1-ASNase, and
weekly blood analysis of ASNase-specific immunoglobulin G (IgG)
was performed from day 17 onward. Blood analysis performed at time
points beyond the final eighth weekly intravenous dose (49 days)3 of 10
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 reflects long-term follow-up of titer levels, up to 45 days later (94 days),
in the absence of additional dosing during that period. In a prophy-
lactic tolerance scheme (where the wild-type protein would be the anti-
cancer therapeutic), mice were first tolerized with ERY1-ASNase for
one or two weekly doses and then crossed to weekly treatment with
wild-type ASNase for the remaining doses. In a therapeutic scheme
(where ERY1-ASNase would itself be the anticancer therapeutic), ERY1-
ASNase was administered weekly throughout the study without cross-
over. Identical weekly doses of filtered wild-type ASNase (0.22-mm
filtered, similarly to ERY1-ASNase) and nonfiltered wild-type ASNase
(as instructed by the package insert) were administered to mice as pos-
itive control groups (filtered, to exclude the possibility that any im-
provements observed could be attributed to the removal of aggregates
from the clinical preparation). Immunogenicity analysis of the dosing
regimens revealed that prophylactic treatment with ERY1-ASNase re-
sulted in the prevention of a marked ASNase-specific humoral response
despite sustained follow-on treatment with wild-type ASNase (Fig. 3A;
corresponding absorbance data in fig. S6). The lack of humoral response
was evidenced by the absence of anti-ASNase antibodies at final blood
collection (94 days), after treatment with one prophylactic dose of
ERY1-ASNase followed by seven subsequent doses of wild-type ASNase,
for a total of eight weekly ASNase treatments (mean anti-ASNase total
IgG log10 titer = 0; P = 0.63 for comparison against the naïve popu-Lorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015lation; anti-ASNase seropositivity of naïve mice in fig. S7). Similarly,
final blood analysis (84 days), after two prophylactic doses followed by
six doses of wild-type ASNase for eight total ASNase treatments, also
yielded mean total anti-ASNase IgG titers (log10 = 0.25) that were not
statistically different from the naïve population (P = 0.97) or from the
single prophylactic ERY1-ASNase treatment regimen (P = 0.60). In
contrast, cohorts administered with nonfiltered or filtered wild-type
ASNase developed more than 2000-fold greater anti-ASNase titer values
(mean total IgG log10 titers = 3.5 and 3.4, respectively, at final blood
analysis; P < 0.0001 for filtered wild-type ASNase treatment against
the naïve population, P < 0.0001 for wild-type ASNase against each
of the prophylactic ERY1-ASNase treatment regimens, respectively).
Similarly to the prophylactically treated groups, mice treated solely
with ERY1-ASNase for all eight doses maintained a low mean
log10 titer value of 1.2, representing a 180-fold reduction compared
to wild-type ASNase (P = 0.007). Notably, the slight increase in mean
anti-ASNase titers after eight weekly ERY1-ASNase treatments as com-
pared to the one- or two-dose prophylactic treatments might be attrib-
utable to a detrimental excess of drug loaded onto erythrocytes during
sustained dosing, given that the circulation time of ERY1-ASNase was
much longer than the separation between consecutive doses. Titers
remained unchanged after final injections for the duration of obser-
vation periods (at least 3 to 6 weeks after final injection).Hematocrit
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Fig. 3. Erythrocyte-binding ASNase is nonimmunogenic and acts as a tolerogen that enables follow-on treatment with WT enzyme. (A) Time
course of anti-ASNase IgG antibody development in plasma of mice administered with eight weekly 15-mg doses of either WT ASNase or ERY1-ASNase or
with one or two tolerogenic doses of ERY1-ASNase followed by WT ASNase for the remaining doses (end-point IgG titers, Mann-Whitney U test: *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001). (B) Time course of anti-ASNase IgG antibody development in plasma of mice administered a dose-sparing regimen of 15 mg
of either WT ASNase or ERY1-ASNase every 3 weeks for a total of four doses (end-point IgG titers, Mann-Whitney U test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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 Given the prolonged pharmacodynamic effect of ERY1-ASNase as
compared to wild-type ASNase, we tested a less frequent dosing
regimen that corresponded to the 25-day therapeutic effect (plasma
asparagine depletion) we observed for ERY1-ASNase. This dosing reg-
imen consisted of treatment with either ERY1-ASNase or wild-type AS-
Nase every 3 weeks for a total of four injections over the course of 63
days. In keeping with the results fromweekly dosing, ERY1-ASNase–treated
mice did not develop significant anti-ASNase IgG titers (mean log10 titer =
0.4) upon regimen completion (66 days), whereas wild-type ASNase treat-
ment resulted in mean anti-ASNase titers 12,600-fold higher (mean log10
titer = 4.5) than that of the ERY1-ASNase–treated group (Fig. 3B).
In addition to the difference in magnitude of anti-ASNase immune
responses, the overall difference in the immunogenicity response rates
of cohorts administered various dosing regimens further highlights the
impact of erythrocyte binding–driven tolerance induction. Immuno-
genicity rate analysis was based on the assessment of ASNase-specific
total IgG titers, where each mouse was judged as having an immune
response after two or more consecutive measurements of total IgG
log10 titer≥2. The resulting depiction of immunogenicity rates further
illustrates the attenuation of immunogenicity incidences after treat-
ment with ERY1-ASNase as compared to wild-type ASNase: anti-
ASNase antibodies were detectable in 100% of mice dosed with filtered
or nonfiltered wild-type ASNase, as measured by total IgG titers, with
95% of these mice developing moderate to high titers (log10 titer levels
between 3 and 5), whereas only 21% of mice (5 of 24) receiving any of
the ERY1-ASNase treatment regimens had detectable levels of anti-
ASNase antibodies, as measured by total IgG titers, and only 4% (1 of
24 mice) among the four different ERY1-ASNase–related treatment
regimens developed a moderate total IgG log10 titer of 4 (Fig. 3C).
As a metric of comparison, anti-ASNase total IgG antibody titers were
detectable in 15% of the naïve population (fig. S7).
Finally, we characterized the IgG subclasses of the measured anti-
body responses upon completion of each dosing regimen (Fig. 3, D
to H). Classification analysis revealed that wild-type ASNase treatment
induced ASNase-specific antibodies distributed across all subclasses,
with IgG1 as the most dominant subclass relative to others. In con-
trast, antibody responses against ERY1-ASNase were blunted across
all IgG subclasses. For those low antibody titers that developed, ERY1-
ASNase treatment resulted in a distribution primarily skewed toward
IgG3. Murine IgG3 has been reported to exhibit the lowest capacity
for Fc receptor activation among the IgG subclasses owing to its re-
stricted binding to only one of the three activating Fcg receptors (23, 24).
Consequently, its reduced ability for potentiating an immune response
may thus be considered as a preferred profile when the limitation of im-
munogenicity is a primary goal. Additionally, murine IgG3 has been
previously reported to be produced in response to T cell–independent
antigens (25). It follows that antigen-specific deletion of T cell help after
tolerizing treatment (15) may thus contribute to a lower relative propor-
tion of T-dependent response.
To assess the antigen specificity of tolerance induction, we per-
formed an analogous crossover study as shown in Fig. 3A, yet using an
irrelevant (nontolerized) antigen for challenge. As previously described,
mice were intravenously administered a single 15-mg dose of either
ERY1-ASNase or wild-type ASNase and, starting 7 days later, were chal-
lenged intravenously with five weekly 10-mg doses of the irrelevant an-
tigen chicken ovalbumin (OVA) (Fig. 4A). Throughout the OVA
challenge regimen, all mice developed robust anti-OVA IgG responses
regardless of the initial priming/tolerizing dose (Fig. 4B), illustratingLorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015that tolerance induction with ERY1-ASNase did not inhibit immune
responses to other antigens. Together with the results of Fig. 3A, these
data demonstrate that erythrocyte-binding antigen induces humoral
immune tolerance in an antigen-specific manner.
To determine whether chronic administration of ERY1-ASNase in-
duced any changes in the immune cell repertoire, we measured hem-
atological parameters in mice after four 15-mg intravenous doses of
ERY1-ASNase or wild-type ASNase every 3 weeks (Fig. 4C). Similar
to weekly administration, chronic ERY1-ASNase administration did not
induce any significant secondary alterations in hematological param-
eters as compared to wild-type ASNase treatment (Fig. 4D; full data in
table S6). Furthermore, to demonstrate the antigen specificity of
ERY1-ASNase–driven tolerance induction after multiple tolerogenic
doses, we subsequently crossed over the mice to intravenous treatment
with OVA. Even in this chronic administration setting, the antigen
specificity of immune tolerance to ASNase was confirmed by the in-
duction of robust humoral responses to follow-on challenge with the
irrelevant antigen OVA in both the ERY1-ASNase– and wild-type
ASNase–treated groups (Fig. 4E).
Because erythrocyte-driven tolerance requires T cell priming and
proliferation to a tolerogenic phenotype (15), we explored the efficacy
of tolerogenesis in aged mice, where less dynamic T cell responses
might hinder such tolerogenic T cell activity (26). Analogous admin-
istration regimens and humoral immunogenicity measurements were
conducted as described above, but with 27-week-old mice as opposed
to 8-week-old mice. After administrations of 15 mg of ERY1-ASNase
or wild-type ASNase every 3 weeks for a total of four doses, wild-type
ASNase–treated mice developed robust anti-ASNase humoral immu-
nity (log10 titer = 5.3), whereas ERY1-ASNase–treated mice developed
responses at the limit of assay detection (log10 titer = 2), representing a
>2100-fold reduction in immunogenicity (Fig. 4, F and G). Such effi-
cacy in an aged immune system suggests that age-dependent immune
populations are not the primary drivers of erythrocyte-driven tolero-
genesis in mice, although clearly, no firm conclusions on the relevance
to aged ALL patients may be drawn before clinical investigation.
Adoptive transfer of 34 million splenocytes from tolerized mice
(prophylactically treated with ERY1-ASNase) into naïve mice did not
confer protection against two subsequent challenges with 15 mg of
wild-type ASNase, suggesting inadequate quantity or insufficient expan-
sion of ASNase-specific Treg cell populations (fig. S8). Although our
results do not categorically preclude a role for Treg cells, they are con-
sistent with our previously published mechanistic results that implicate
T cell deletion and anergy as the primary drivers of erythrocyte-binding
tolerance induction (15). Rather, these results may suggest that transfer
of splenocytes without ASNase-reactive T cells (due to deletion) or
immunologically unresponsive (anergic) populations of T cells is in-
effective in suppressing immune responses in recipient animals.DISCUSSION
In these studies, we establish the feasibility of inducing antigen-specific
tolerance to a clinically relevant, immunogenic protein drug by way of
administration of an erythrocyte-binding variant of the drug. To this
end, we engineered a variant of the highly foreign enzyme E. coliASNase,
used in the treatment of ALL, which is capable of binding to erythrocytes
in situ upon injection. We demonstrated that the enzymatic activity of
the ASNase variant was unaltered despite the chemical modification6 of 10
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 made to impart binding to the erythrocyte surface.With a focus on clin-
ical translation of the erythrocyte binding approach, animal modeling
was performed analogous to relevant primary end points reported for
recent clinical trials involving novel ASNase treatments (27) (U.S. Na-
tional Institute of Health clinical trial identifiers NCT00784017 and
NCT01643408; E.U. clinical trials database numbers 2005-000658-56
and 2009-012584-34). In recent ALL ASNase trials, primary end points
relating to drug pharmacodynamics, such as reduction of blood as-
paragine or activity of ASNase, have been accepted because it has been
established that high anti-drug antibody response rates can hinder
clinical efficacy because of premature clearance of ASNase. Thus, ourLorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015in vivo studies were similarly designed to include metrics such as aspar-
agine depletion (drug efficacy) and antigen-specific immune response
(safety). Additional safety metrics, such as immunophenotyping and
hematological analyses, were also performed.
We demonstrate that engineering ASNase to bind erythrocytes
both extends the pharmacodynamic effect of the drug 10-fold in mice
and induces durable antigen-specific tolerance to the drug. We show
that prophylactic treatment with ERY1-ASNase antigen-specifically
abrogates development of antibody titers by >1000-fold as compared
to treatment with the clinical wild-type ASNase alone. Although fold
changes in an animal model are not expected to be predictive ofDay:
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Fig. 4. ERY1-ASNase treatment induces antigen-specific tolerance in a nontoxic and age-independent manner. (A) Mice were assessed for their
capacity to respond to the irrelevant (nontolerized) antigen OVA after a single tolerogenic dose of ERY1-ASNase. (B) Time course of the development of
anti-OVA total IgG in mice tolerized with 15 mg of ERY1-ASNase or WT ASNase and challenged with five weekly intravenous doses of OVA. (C) Mice were
assessed for hematological parameters and for capacity to respond to the irrelevant antigen OVA after chronic intravenous administration with 15 mg of
ERY1-ASNase or WT ASNase every 3 weeks for a total of four injections. (D) Hematological parameters at day 87 (data presented as ERY1-ASNase fold
increase over WT ASNase; Student’s two-tailed t test, P > 0.05 for all parameters, n = 3 to 5). (E) Quantification of end-point antigen-specific total IgG
responses to a challenge with the irrelevant T cell–dependent antigen OVA (n = 3 to 5, Mann-Whitney U test). (F and G) Time course of anti-ASNase
IgG development in plasma of aged (27-week-old) mice receiving 15 mg of ERY1-ASNase or WT ASNase, represented as (F) log10 titer (n = 3 to 4,
Mann-Whitney U test, *P < 0.05) and (G) absorbance reading of 1:100 dilution of plasma [n = 3 to 4; analysis of variance (ANOVA), ****P < 0.0001)]; dotted
lines indicate mean values for the naïve population (n = 149).7 of 10
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 equivalent changes in humans, we consider that the robust antibody
reduction consistently demonstrated in tolerized groups despite mul-
tiple variations in dosing scheme and age merits further exploration
in additional preclinical models, such as in nonhuman primates. The
prevention of antigen-specific humoral immune response demonstrated
herein has substantial relevance to the clinic, where anti-ASNase neu-
tralizing antibodies are associated with poorer treatment prognosis for
ALL patients (17, 21, 22). Others have sought to engineer similar strat-
egies to overcome the clinical immunogenicity hurdles of ASNase by
entrapping the drug in donor erythrocytes ex vivo and infusing the
manipulated cells into patients. This approach, which exploits shield-
ing from the immune system, has been reported to reduce allergic re-
sponses and prolong pharmacodynamic effects in the clinic (27). It remains
to be seen whether such an approach results in durable prevention of
anti-ASNase antibodies upon reexposure, development of which may
suggest that external co-display of therapeutic protein and tolerogenic
cell surface signaling is indispensable for tolerance induction.
Notably, we showed that even a single dose of the erythrocyte-
binding ASNase yields long-term (94 days) tolerance to seven subse-
quently administered doses of wild-type ASNase. Although more work
needs to be done to determine the absolute duration of a single tol-
erogenic dose of ERY1-ASNase, we demonstrate tolerance induction
over time scales that are about fourfold longer than the reported
median survival rates of single-dose wild-type ASNase therapy in mouse
models of ALL, suggesting that our dosing regimens are relevant to
preclinical ALL modeling (28). We have previously demonstrated that
our erythrocyte binding strategy induces antigen-specific CD4 and
CD8 T cell tolerance through exhaustion and deletion mechanisms
(15). Here, we hypothesized that T cell deletion mediated by erythro-
cyte binding would result in measurable decreases in T cell–dependent
humoral immunity. The current data support this hypothesis and sug-
gest that abolishing antigen-specific T cell help to B cells may effectively
prevent the development of anti-drug antibodies—even in the challenging
example when the drug is an E. coli protein. Although the complete
mechanism of tolerance induction by erythrocyte binding strategies is
not yet fully understood, we have shown that natural apoptotic signals
such as annexin V binding and programmed cell death 1 (PD-1) play
a role in the antigen-specific CD4 and CD8 T cell deletion after admin-
istration of erythrocyte-binding antigen (15). Other recent antigen-specific
strategies, in addition to ours, have yielded promising results by ex-
ploiting apoptosis signaling pathways to achieve tolerance. For exam-
ple, liposomal formulations that co-display antigen with defined
amounts of the apoptosis signal phosphatidylserine have been demon-
strated to reduce dendritic cell maturation by inhibition of CD86 and
CD40 up-regulation (29). Similarly, synthetic co-display of antigen
and glycan ligands of the B cell siglec CD22 has been shown to en-
hance B cell apoptosis and thereby reduce antibody titers by 1 to 3
log10 after two challenges (30). Given that erythrocytes are densely
decorated with sialic acids (siglec ligands) and up-regulate phosphati-
dylserine during eryptosis, it is possible that our strategy exploits
multiple, natural, apoptosis signaling pathways during induction of
antigen-specific tolerance. Others have aimed to achieve more phys-
iologically complex displays of natural apoptosis signaling by combining
antigen delivery with cell-based techniques. For example, apoptosis
signaling has been implicated in the encouraging decreases in pathogen-
ic antigen–specific T cell responses and expansion of Treg cell popula-
tions observed after delivery of cells chemically conjugated with antigen
ex vivo (31, 32) or after delivery of antigen and healthy phagocytesLorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015following systemic sublethal irradiation (33). However, the additional
complexities and potential risks relating to these techniques, including
sourcing of self or donor cells, ex vivo manipulation of human tissue
before reintroduction into the patient, and systemic irradiation, may
hinder their translation to the clinic.
Our erythrocyte binding approach is different from previous antigen-
specific approaches in that we combine the simplicity of defined phar-
maceutical formulations with the more complex cellular signaling of
cell-based techniques while still avoiding ex vivo sourcing or manip-
ulation. Cell binding with our approach occurs in situ after simple in-
jection of the protein conjugate. By engineering the clinical therapeutic
enzyme E. coli ASNase to bind both healthy and apoptotic erythro-
cytes in situ, we can exploit natural apoptosis signaling as the erythrocytes
age to induce humoral immune tolerance to a highly foreign therapeu-
tic protein. We have demonstrated aspects of erythrocyte-binding
tolerance with model proteins and autoantigens (15) and here with the
therapeutic protein ASNase; however, realization of the platform po-
tential of this technology will require future work with additional pro-
tein targets. Although we acknowledge the limitation of using inbred
mouse strains to study immune responses toward an antigen that is
clinically administered to a heterogeneous human haplotype popula-
tion, it is noted that the degree of antigenicity (corollary to evolution-
ary distance) between E. coli and mice is similar to that between E. coli
and humans. Our results have potential implications for immunogenic
life-saving therapies, such as ASNase in ALL and enzyme replacement
therapies in rare diseases, where neutralizing antibody responses may
leave few or no options for salvage treatment with another therapy;
ASNase from the bacterium Erwinia chrysanthemi is currently used clin-
ically as a salvage therapy in ALL, albeit at the risk of developing
additional anti-ASNase antibodies toward this foreign enzyme (34).
Moreover, prolonged pharmacodynamics may contribute to improving
treatment efficacy for some protein therapies. Thus, the tolerogenic and
dose-sparing attributes of ERY1-ASNase illustrated here highlight the
potential of the erythrocyte binding technology to improve the safety
and efficacy of immunogenic therapeutic proteins.MATERIALS AND METHODS
Experimental design
The overall hypothesis we aimed to answer was if induction of
humoral immune tolerance to an immunogenic therapeutic protein
could be induced by engineering the protein for erythrocyte binding,
thus harnessing the tolerogenic potential of apoptotic cell–driven tol-
erance. BALB/cOlaHsd mice were used because of their robust IgG
responses to ASNase.
Animals. Swiss Veterinary authorities previously approved all ani-
mal procedures. Eight- to 12-week-old female BALB/cOlaHsd mice
(Harlan) were used for all in vivo studies, except for aging effect studies,
where mice were used at 27 weeks of age. Mice were housed in the
Ecole Polytechnique Fédérale de Lausanne (EPFL) Animal Facility.
Exclusion criteria from any study were 15% weight loss or affliction
with spontaneous disease or malaise judged as irrelevant to the study,
as directed by the Swiss Federal Veterinary Authority; no mice met the
exclusion criteria during the studies. All mouse studies were performed
with age-matched control groups.
ASNase conjugation. The erythrocyte-binding ERY1 peptide (19)
(H2N-WMVLPWLPGTLDGGSGCRG-CONH2) was custom-synthesized8 of 10
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 (GenScript) to result in conjugation of the ERY1 peptide to the lysine
residues of ASNase: the underlined sequence is the 12-residue erythrocyte-
binding domain, GGSG serves as a linker to the sulfhydryl of the cys-
teine residue used for conjugation (bold), and the flanking arginine
residue serves to lower the pKa and thus increase the reactivity of the
sulfhydryl group (35). Clinical wild-type ASNase from E. coli (Asparaginase
5000, Medac GmbH) was resuspended in 2 ml of sterile 0.9% saline
(B. Braun) and diluted with phosphate-buffered saline (PBS) to a concen-
tration of 5 mg/ml. Ten molar equivalents of SMCC [sulfosuccinimidyl-
4-(N-maleimidomethyl) cyclohexane-1-carboxylate; Thermo Scientific]
dissolved in sterile dimethylformamide was added to the solution. The
reaction was incubated for 1 hour at room temperature and desalted
by two passes through Zeba Desalt spin columns (Thermo Scientific).
Three molar equivalents of ERY1-Cys dissolved in 3 M guanidine hy-
drochloride was then added to the desalted, SMCC-conjugated ASNase;
incubated at room temperature for 30 min; and passed through a Zeba
Desalt spin column (Thermo Scientific) twice. The product was sterile-
filtered (0.2 mm), aliquoted, and stored at −20°C. Protein concentration
was determined by bicinchoninic acid assay (Thermo Scientific). The
specific activities of wild-type ASNase and ERY1-ASNase were deter-
mined by a fluorometric asparaginase activity assay kit (BioVision),
using aspartate as a standard.
In vivo circulation and binding. Fifteen micrograms of either
ERY1-ASNase or wild-type ASNase in 100 ml of 0.9% saline (B. Braun)
was injected into the tail vein of mice anesthetized with isoflurane. At
predetermined time points, 2.5 ml of whole blood was collected by a
small tail incision and diluted 50-fold in cold PBS with bovine serum
albumin (10 mg/ml). Erythrocyte-bound ASNase levels were directly
assayed by flow cytometry on a CyAn ADP analyzer (Beckman Coulter).
Samples were kept on ice to limit ERY1-ASNase dissociation from the
erythrocyte surface. Labeling was performed with polyclonal rabbit
anti-ASNase (Abnova) and Alexa Fluor 488 chicken anti-rabbit IgG
(Life Technologies). For apoptosis assays, annexin V–Cy5 staining was
performed on ice for 5 min before analysis. For pharmacokinetic studies,
flow cytometer settings were fixed for the duration of the study.
Immunogenicity assessment. For each dosing regimen, a 100-ml
volume containing 15 mg of either ERY1-ASNase or wild-type ASNase
in 0.9% saline was injected into the tail vein of anesthetized mice. Blood
was collected from either the submandibular or the saphenous vein at
predetermined time points; all groups were bled via the same route on
the same day, and routes were alternated each time to minimize irri-
tation. Care was taken to minimize volume of blood sampling. Blood
was collected into EDTA tubes, and plasma was stored at −20°C. For
analysis of general hematological parameters, blood samples were di-
rectly diluted twofold with 0.9% saline and analyzed on an Advia 120
Hematology System (Siemens).
Plasma samples were assayed for the presence of ASNase-specific
IgG antibodies by direct enzyme-linked immunosorbent assay (ELISA),
using horseradish peroxidase–conjugated goat-anti mouse IgG, IgG1,
IgG2a, IgG2b, and IgG3 (all from Southern Biotech). ELISA steps
were performed at room temperature, and 2.5% casein (w/v) was used
as a blocking and binding buffer. In brief, ASNase-coated plates were
blocked for 2 hours, washed extensively with PBS-Tween, incubated with
diluted plasma samples for 2 hours, washed, incubated with detection
antibody for 1 hour, washed, developed with 3,3′,5,5′-tetramethylbenzidine
substrate (eBioscience) for 30 min, and quenched with 9.8% (v/v) H2SO4
in water. IgG titers were calculated as the dilution of serum that produced
an absorbance twofold above background. Total IgG anti-ASNase char-Lorentz et al. Sci. Adv. 2015;1:e1500112 17 July 2015acterization of a naïve mouse population (n = 149) yielded 15% of mice
with a log10 titer ≥2. Total IgG log10 titer <2 was thereby considered
as not meaningful in discerning immunity from nonimmunity, and
dilutions were consequently begun at 100-fold to minimize blood vol-
ume collected from animals. After the initial 100-fold dilution, serial
dilutions were performed at 10-fold thereafter. In the study with 27-week-old
mice, if an animal developed antigen-specific log10 titers ≥5, then it
was not reinjected with antigen to avoid anaphylactic responses upon
reinjection.
Statistical analysis. All flow cytometry data were analyzed in FlowJo
(v9.7.5, Tree Star Inc.). Prism (v5, GraphPad) was used for graphical
representation of data, and both Prism and R (v 3.0.2, The R Foun-
dation for Statistical Computing) were used for statistical testing. Mann-
Whitney U tests were used for interpreting FACS (fluorescence-activated
cell sorting) population and end-point IgG titer data, two-way ANOVA
was used for interpreting IgG absorbance data, Student’s two-tailed t
test was used for interpreting hematology data, and log-rankMantel-Cox
tests were used for interpreting immunogenicity rate data.
Flow cytometry. Cell samples were washed in PBS before live/dead
staining for 20 min on ice; the cells were then surface-stained for 20 min
on ice in the presence of 2.4G2 hybridoma supernatant, fixed in 2%
paraformaldehyde for 15 min on ice, and washed with PBS supple-
mented with 2% fetal bovine serum before analysis. For annexin V
staining, nonfixed samples were incubated with annexin V–Cy5 for 5 min
in annexin V staining buffer (BioVision) before analysis. Samples were
analyzed on a CyAn ADP Analyzer (Beckman Coulter) or an LSR-II
flow cytometer (BD Biosciences).
Additional materials and methods. Flow cytometry reagents and
LC-MS for quantification of plasma asparagine concentrations are de-
scribed in detail in Supplementary Materials and Methods.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/1/6/e1500112/DC1
Materials and Methods
Fig. S1. Flow cytometry gating strategy for leukocyte populations in blood.
Fig. S2. Flow cytometry gating strategy for Treg cells in the blood, bone marrow, and spleen.
Fig. S3. Flow cytometry gating strategy for B cell populations in the spleen.
Fig. S4. Flow cytometry gating strategy for myeloid populations in the spleen and bone marrow.
Fig. S5. Flow cytometry gating strategy for B cell populations in the bone marrow.
Fig. S6. Erythrocyte-binding ASNase is nonimmunogenic and acts as a tolerogen that enables
follow-on treatment with wild-type enzyme.
Fig. S7. Anti-ASNase seropositivity analysis in naïve BALB/cOlaHsd mice.
Fig. S8. Adoptive transfer of splenocytes from ERY1-ASNase tolerized mice does not transfer
tolerance.
Table S1. Hematology characterization after short-term treatment regimens.
Table S2. T cell characterization after short-term treatment regimens.
Table S3. B cell characterization after short-term treatment regimens.
Table S4. Myeloid cell characterization after short-term treatment regimens.
Table S5. B cell characterization after short-term treatment regimens.
Table S6. Hematology characterization after long-term treatment regimens.REFERENCES AND NOTES
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